ClinicalTrials.gg
RecruitingNCT04360694Updated Jun 12, 2024

RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis (REAL-LIFE)

An interventional study of Incremental hemodialysis and Conventional hemodialysis in End Stage Renal Disease on Dialysis, sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Kidney Failure, Chronic with a site in Italy — 14 open to participants now, 19 under way, 4 of them phase 3. Kidney Failure, Chronic · Italy.

Planned enrollment
20th of 59
190 · median 80
Started
2021
with 3 others
No phase
17 of 75
5 open now
Primary completion
2026-12
later than 5 of 18 live
Registered
51st of 75
by date
Lead sponsor
2 of 75
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Among the 75 studies in Kidney Failure, Chronic with a site in Italy, this one is the 20th largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2021, is one of 17 with no phase, reaches primary completion later than 5 of the 18 other live ones, and was the 51st registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

14 of the 75 studies in Kidney Failure, Chronic with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Kidney Failure, Chronic with a site in Italy, or all of them as a file.
02

Study summary

Background: The thrice-weekly hemodialysis (HD) regimen is widely accepted as a standard prescription. The concept of incremental dialysis has been established as a possible alternative for patients with preserved diuresis and end-stage renal failure in need of HD. The main problems related to prescription of incremental HD are an arbitrary use of infrequent regimens and the lack of clear standards for incorporating residual kidney function (RKF) in the assessment of HD dose. Several models have been proposed for prescription of incremental dialysis. The latest, the variable target model (VTM), gives more clinical weight to the RKF and allows less frequent HD treatments at lower RKF. Despite increasing evidence derived from observational studies to support the use of incremental HD, RCTs are lacking and, therefore, urgently needed.

Methods/Design:

The Department of Nephrology, Dialysis and Transplantation of the Azienda Ospedaliero Universitaria Consorziale Policlinico, Bari, Italy and the EUDIAL Working Group of the European Renal Association - European Dialysis Transplant Association (ERA-EDTA) are starting a randomized clinical trial (RCT) in incident HD patients, whose name is "REAL LIFE", by using the acronym of its whole definition: RandomizEd clinicAL triaL on the effIcacy and saFety of incremental haEmodialysis. REAL LIFE is a pragmatic, prospective, multicentre, open label RCT, investigator-initiated, comparing the intervention arm (incremental HD) with the control arm (standard 3HD/wk). The trial, originally conceived by experts at the Division of Nephrology of the Miulli General Hospital, Acquaviva delle Fonti, Italy, consists in starting the HD treatment adopting the new incremental approach guided by the VTM. The primary outcome is the survival of kidney function, with the event defined as urinary output (UO) ≤ 200 mL/day, confirmed by a further collection after 2 weeks to exclude temporary illness.

Discussion: REAL LIFE will enable the investigators to know with the highest level of scientific evidence the safety and efficacy of an incremental approach to the start of HD treatment.

Read the detailed description

The majority of dialysis patients starting hemodialysis (HD) are currently treated with a fixed dose thrice-weekly HD (3HD/wk). The 3HD/wk regimen has been assumed, until recently, almost as a dogma in the dialysis community. Incremental HD is based on the simple idea of adjusting its dose according to the metrics of RKF. REAL LIFE is a pragmatic, prospective, multicentre, open label RCT, investigator-initiated, comparing the intervention arm (incremental HD) with the control arm (standard 3HD/wk). A Variable Target Model (VTM) has been suggested, which gives more clinical weight to the RKF and allows less frequent HD treatments in patients with lower RKF. The investigators recommend to start and keep on with once-weekly HD, which should be possible until residual renal urea clearance (KRU) falls below 2.5 - 3.0 mL/min/35 L, i.e., glomerular filtration rate (GFR) ≈ 4 mL/min/1.73 m2.

The primary outcome is the survival of kidney function, with the event defined as urinary output (UO) ≤ 200 mL/day, confirmed by a further collection after 2 weeks to exclude temporary illness. Secondary outcomes are: composite primary cardiovascular endpoint (cardiovascular death, non fatal myocardial infarction and/or or non fatal stroke); intima-media thickness of the carotid arteries; specific cardiomyopathy control; RKF preservation; patients survival; hospital admissions; anemia control; mineral and bone disorder control, and middle molecules removal.

The sample size calculation is based on the primary outcome "presence of anuria". The assumptions for calculating the sample size, derived from data of Teruel Briones et al., are the following:

  • Percentage of subjects who developed anuria in the experimental group (incremental HD): 25%
  • Percentage of subjects who developed anuria in the control group (standard 3HD/wk): 51%
  • Power: 0.8
  • Ratio: 1:1
  • Non-compliance: 20%
  • Total expected sample size: 190 (95 participants in each group)

The assessment of the key kinetic parameters as well as the guide to the selection of operative parameters, as required to get the required equilibrated Kt/V (eKt/V = 1.05), will be done by using SPEEDY, a spreadsheet prescription tool that uses essentially the same equations used by Solute Solver, the software based on the double pool UKM recommended by the 2015 KDOQI guidelines. SPEEDY is freely available at the European Nephrology Portal (ENP).

The link is https://enp-era-edta.org/174/page/home. The control arm includes patients put on a thrice-weekly HD schedule, as detailed above. The dialysis dose (eKt/V) should be about 1.05.

PICO question:

Participants with CKD-EPI GFR ≤ 10 ml/min and daily urine output > 600 ml Intervention: one or two weekly hemodialysis (as detailed above) Comparator: three weekly hemodialysis (as per standard practice and as detailed above) Outcome: Residual renal function

03

Conditions studied

  • End Stage Renal Disease on Dialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged > 18 years
  • Start of maintenance hemodialysis treatment due to advanced CKD stage 5D
  • Patients who are about to start HD or have already started HD within a period of ≤ 2 weeks
  • \<= 10 mL/min/1.73 m2, as estimated by means of CKD-EPI formula.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Acute kidney injury or acute on chronic kidney injury
  • higher than 10 mL/min/1.73 m2
  • UO \< 600 mL/day
  • Already treated with other replacement therapies (peritoneal dialysis or kidney transplant)
  • Unable or unwilling to give .
  • Unable to comply with trial procedures, e.g., collection of UO.
  • Likely survival prognosis or planned modality or centre transfer \< 6 months.
  • Patients who are in the waiting list for a living kidney transplant
  • Associated diseases: active neoplastic disease; congestive heart failure (type IV , ≤ 30%) requiring high ultrafiltration volumes per session.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Incremental hemodialysis

    Procedure: Incremental hemodialysis. It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression

    Procedure: Incremental hemodialysis

  • Active comparator
    Conventional hemodialysis

    Procedure: Conventional hemodialysis. It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).

    Procedure: Conventional hemodialysis

Interventions

  • ProcedureIncremental hemodialysis

    95 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.

  • ProcedureConventional hemodialysis

    95 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.

06

What researchers measure

Primary outcomes

  1. Number of participants whose kidney function remains >200 ml

    The survival of kidney function is defined as a time to the event (anuria): the anuria is defined as urinary output (UO) ≤ 200 mL/day, confirmed by a further collection after 2 weeks to exclude temporary illness

    Time frame: 24 months

Secondary outcomes

  1. Number of participants who develop cardiovascular death, non fatal myocardial infarction and/or or non fatal stroke (composite outcome)

    Cardiovascular death, non fatal myocardial infarction and/or or non fatal stroke

    Time frame: 24 months

  2. Mean value of intima-media thickness of the carotid arteries of participants at end of treatment and change from beginning to end of treatment

    Echographic evaluation of intima-media thickness of the carotid arteries

    Time frame: 12 and 24 months

  3. Value of left ventricular ejection fraction established with cardiac ultrasound at end of treatment and change from beginning to end of treatment

    Ecocardiography reporting data on the left ventricular ejection fraction (LVEF)

    Time frame: 12 and 24 months

  4. Value of residual kidney function (RKF) preservation established by the slope of decline of residual renal urea clearance

    The rate of decline in RKF defined as the slope of decline of residual renal urea clearance

    Time frame: 24 months

  5. Number of people who die

    The follow-up time will be determined in days. It will be defined as the difference in days from the date of the end of the follow-up minus the date of the baseline visit. Events will be counted either as deaths (follow-up of less than 24 months) or as end of the follow-up

    Time frame: 24 months

  6. Number of people who are hospitalized

    The number of admissions will be registered.

    Time frame: 24 months

  7. Value of hemoglobin in participants at end of treatment and change from beginning to end of treatment

    The hemoglobin levels (in g/dl) will be measured.

    Time frame: Every month

  8. Value of serum phosphorus, calcium and parathyroid hormone in participants at end of treatment and change from beginning to end of treatment

    Serum phosphorus and calcium levels (in mg/dl), and intact PTH (in pg/dl) will be measured.

    Time frame: Every month and three months

  9. Value of serum beta 2 microglobulin (middle molecule) at end of treatment and change from beginning to end of treatment

    The rate of change in serum beta 2 microglobulin in time will be evaluated

    Time frame: Every three months

  10. Value of p-cresyl sulfate and inoxyl sulfate at end of treatment and change from beginning to end of treatment (uraemic toxins variation)

    Variation of uremic toxins including p-cresyl sulfate and inoxyl sulfate

    Time frame: Every six months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Casino FG, Basile C. The variable target model: a paradigm shift in the incremental haemodialysis prescription. Nephrol Dial Transplant. 2017 Jan 1;32(1):182-190. doi: 10.1093/ndt/gfw339. PubMed 27742823 ↗
  • Basile C, Casino FG, Kalantar-Zadeh K. Is incremental hemodialysis ready to return on the scene? From empiricism to kinetic modelling. J Nephrol. 2017 Aug;30(4):521-529. doi: 10.1007/s40620-017-0391-0. Epub 2017 Mar 23. PubMed 28337715 ↗
  • Basile C, Casino FG; EUDIAL Working Group of ERA-EDTA. Incremental haemodialysis and residual kidney function: more and more observations but no trials. Nephrol Dial Transplant. 2019 Nov 1;34(11):1806-1811. doi: 10.1093/ndt/gfz035. No abstract available. PubMed 30805639 ↗
  • Casino FG, Basile C. A user-friendly tool for incremental haemodialysis prescription. Nephrol Dial Transplant. 2018 Jun 1;33(6):1074-1075. doi: 10.1093/ndt/gfy081. No abstract available. PubMed 29672745 ↗
  • Casino FG, Lopez T. The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant. 1996 Aug;11(8):1574-81. PubMed 8856214 ↗
  • Teruel-Briones JL, Fernandez-Lucas M, Rivera-Gorrin M, Ruiz-Roso G, Diaz-Dominguez M, Rodriguez-Mendiola N, Quereda-Rodriguez-Navarro C. Progression of residual renal function with an increase in dialysis: haemodialysis versus peritoneal dialysis. Nefrologia. 2013;33(5):640-9. doi: 10.3265/Nefrologia.pre2013.May.12038. English, Spanish. PubMed 24089155 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 67 months is above that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2020
First posted
Apr 24, 2020
StartActual
May 10, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04360694
Lead sponsor
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Collaborators
European Renal Association - European Dialysis and Transplant Association
Responsible party
Loreto Gesualdo, MD (Full Professor of Nephrology University of Bari Aldo Moro - Head of the Nephrology, Dialysis and Transplantation Unit, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari) — Principal investigator
First posted
Apr 24, 2020
Start date
May 10, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 12, 2024

Study contacts

Loreto Gesualdo, MD
Contact
loreto.gesualdo@uniba.it
+390805594041
Domenico Roselli, MSc
Contact
domenico.roselli@policlinico.ba.it
+390805592778

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion